Failure to Satisfy Listing Rule (Form 8-K)

Nasdaq Delisting Notification

On August 4, 2026 Lexaria Bioscience Corp. (the "Company") received a notification (the "Notification") from the Nasdaq Capital Market ("Nasdaq") that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain a $1.00 minimum bid price, (the "Bid Price Requirement") within the 180 day compliance period provided under Nasdaq Listing Rule 5810(c)(3)(A), it would be delisted from the Nasdaq, subject to any request for a hearing to appeal such determination, which hearing request would stay the suspension of the Company's shares from being delisted.

In anticipation of the Notification, the Company completed a reverse stock split on August 3, 2026 (as announced on July 30, 2026) and, since that time, the Company's shares of common stock have been trading on Nasdaq under CUSIP number 52886N604 with a minimum bid price that is currently above the Bid Price Requirement. The Company has also filed its request for a hearing and paid the required fee in order to suspend the delisting of the Company's shares from Nasdaq and to allow for the additional trading days necessary to regain the Bid Price Requirement. As of the date and time of this filing, the Company expects to regain compliance with the Nasdaq rules and requirements prior to any potential hearing date and expects its shares will remain trading on Nasdaq without interruption.